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Abstract
Purpose: To examine the prevalence of, and factors associated with, atypical antipsychotic use 
among U.S. pregnant women, and potential associations between early pregnancy atypical 
antipsychotic use and risk for 14 birth defects.
Methods: We analyzed data from the National Birth Defects Prevention Study (1997–2011), a 
U.S. population-based case-control study examining risk factors for major structural birth defects.
Results: Atypical antipsychotic use during pregnancy was more common among women with 
pre-pregnancy obesity, and women who reported illicit drug use before and during pregnancy, 
smoking during pregnancy, alcohol use during pregnancy, or use of other psychiatric medications 
during pregnancy. We observed elevated associations (defined as a crude odds ratio [cOR] ≥2.0) 
between early pregnancy atypical antipsychotic use and conotruncal heart defects (6 exposed 
cases; cOR: 2.3, 95% confidence interval [CI]: 0.9–6.1), and more specifically Tetralogy of Fallot 
(3 exposed cases; cOR: 2.5, 95% CI: 0.7–8.8), cleft palate (4 exposed cases; cOR: 2.5, 95% CI: 
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0.8–7.6), anorectal atresia/stenosis (3 exposed cases; cOR: 2.8, 95% CI: 0.8–9.9), and 
gastroschisis (3 exposed cases; cOR: 2.1, 95% CI: 0.6–7.3).
Conclusions: Our findings support the close clinical monitoring of pregnant women using 
atypical antipsychotics. Women treated with atypical antipsychotics generally access healthcare 
services before pregnancy; efforts to reduce correlates of atypical antipsychotic use might improve 
maternal and infant health in this population.
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1. Introduction
Atypical or second-generation antipsychotic medications are used as first-line treatment to 
manage primary psychotic disorders and phases of bipolar disorders (ACOG, 2008; Poo and 
Agius, 2015). These medications are also used as pharmacological adjuncts to manage the 
symptoms of treatment-resistant unipolar major depression and anxiety disorders (Demler, 
2011; Park et al., 2017; Toh et al., 2013). Atypical antipsychotics have fewer neuromuscular 
side effects than typical first-generation antipsychotics (Leucht et al., 1999), and for this 
reason, are now more commonly prescribed for mental disorders than typical antipsychotics 
(Fisher et al., 2014; Park et al., 2017). Onset of these mental health disorders often begins in 
adolescence or early adulthood, and many of the disorders that can be treated with 
antipsychotics are more common in women than men (NIMH, 2018). However, the 
prevalence of atypical antipsychotic use among the population cumulatively affected by 
these mental health disorders in the United States is largely unknown.
Previous studies suggest a growing proportion of pregnant women are prescribed atypical 
antipsychotics. In Denmark, filled prescriptions for antipsychotic medications during 
pregnancy have increased from 1.5 per 1,000 pregnancies to 3.8 per 1,000 pregnancies with 
a delivery from 2000–2016 (Damkier et al., 2018). In the United States, Park and colleagues 
(2017) showed an increase in atypical antipsychotic prescription claims among Medicaid-
insured U.S. pregnant women between 2001 (0.4%) and 2010 (1.3%). The prevalence of 
atypical antipsychotic medication use among more representative populations of U.S. 
pregnant women is unclear, as most available U.S. estimates were drawn from Medicaid-
insured populations and based on prescription claims data (Epstein et al., 2013; Park et al., 
2017; Toh et al., 2013). The increase in potential use suggests it is important to understand 
these mothers’ characteristics. Women who use atypical antipsychotics during pregnancy 
and have mental disorders may have other factors (e.g., unintended pregnancies, pre-
pregnancy obesity, diabetes, substance use; Habermann et al., 2013; Park et al., 2017; 
Petersen et al., 2016; Reis and Kallen, 2008) associated with poor pregnancy and infant 
outcomes. Pregnant women who use atypical antipsychotics may also more commonly have 
concomitantly-prescribed psychotropic medications (e.g., anxiolytics, anticonvulsants, 
antidepressants) (Park et al., 2017; Petersen et al., 2016; Sadowski et al., 2013). Notably, 
most estimates of maternal factors associated with atypical antipsychotic use are drawn from 
non-U.S. populations, where prenatal and mental health care differ from the United States.
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There is a critical need to understand these medications’ safety during pregnancy given their 
potentially increased use among pregnant women. Studies have suggested that there may be 
an increased risk for any major structural birth defect (Bellet et al., 2015; Coughlin et al., 
2015; Habermann et al., 2013; Huybrechts et al., 2016; Kulkarni et al., 2014; Petersen et al., 
2016; Reis and Kallen, 2008; Sadowski et al., 2013; Terrana et al., 2015) or any structural 
congenital heart defect (Coughlin et al., 2015; Habermann et al., 2013; Huybrechts et al., 
2015) associated with use of antipsychotic medications generally during pregnancy. 
However, few data are available about atypical antipsychotic medication use specifically 
during early pregnancy (the period of organogenesis) and the risk for specific birth defects. 
Examining associations between maternal early pregnancy atypical antipsychotic use and 
specific birth defects is critical because potential teratogens rarely result in increased risks 
for all defects; instead, teratogens alter specific developmental processes that result in 
specific birth defects (Khoury et al., 1992).
We used data from the U.S. population-based National Birth Defects Prevention Study to 
examine the prevalence of, and maternal factors associated with, atypical antipsychotic 
medication use among pregnant women. Given limited research on atypical antipsychotic 
use and risk for specific birth defects, we conducted an exploratory analysis that examined 
possible associations between early pregnancy atypical antipsychotic use and risk for 
specific defects.
2. Materials and methods
2.1. Participants
We analyzed data from the National Birth Defects Prevention Study (NBDPS) on 
pregnancies ending on or after October 1, 1997, through those with an estimated date of 
delivery (EDD) on or before December 31, 2011. The NBDPS was a population-based, 
multi-site case-control study that examined risk factors for more than 30 major structural 
birth defects with unknown etiologies; infants with recognized single-gene disorders or 
chromosomal abnormalities were excluded (Reefhuis et al., 2015). Ten sites located in 
Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, 
Texas, and Utah collaborated on the NBDPS. Each site ascertained data on pregnancies 
affected by selected birth defects from active, population-based birth defects surveillance 
systems using standard, detailed case definitions. Birth defect cases included live births (all 
sites), stillbirths (all sites except NY before 2000 and NJ), and terminations (all sites except 
GA before 1999, MA before 2011, NY before 2000, and NJ). Clinical data were abstracted 
from medical records to confirm that birth defect(s) met eligibility criteria, and clinical 
geneticists and other expert clinicians then classified cases into homogeneous defect 
categories using procedures described elsewhere (Rasmussen et al., 2003; Reefhuis et al., 
2015). Controls were liveborn infants without major birth defects who were randomly 
sampled from the same geographic location and study years as birth defect cases using data 
from hospital birth logs or vital records. More detailed information about the design of 
NBDPS has been published previously (Rasmussen et al., 2003; Reefhuis et al., 2015). All 
participating institutions received IRB approval, and consent was obtained.
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Mothers were invited to participate in an English or Spanish computer-assisted telephone 
interview 6 weeks to 24 months after their EDD (participation rate: 67% for case and 65% 
for control mothers) (Reefhuis et al., 2015). The interview included questions to assess 
maternal sociodemographic factors, health and pregnancy history, behavioral exposures, and 
over-the-counter and prescription medication, supplement, and vitamin use. The median 
time to interview was 11 months for case and 9 months for control mothers. Mothers 
reported information about medication use (start/stop dates, duration, and frequency) before 
and during pregnancy using calendar dates or pregnancy months (consecutive 30-day 
intervals during the time before and during conception). Pregnancy exposure timing was 
based on the estimated date of conception.
Atypical antipsychotic exposure was defined as maternal report of any use of ≥1 of the 
following medications: aripiprazole, asenapine, clozapine, iloperidone, lurasidone, 
olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone. Case and control mothers 
may have reported medications when asked about any: (a) medications taken before and 
during pregnancy or (b) diseases or illnesses occurring before and during pregnancy, with 
subsequent probing for which medications were used to treat the reported condition. Other 
medication data were collected using the same procedures. Anxiolytic, anticonvulsant, and 
antidepressant exposure were each defined using the National Institute of Mental Health 
medication list (NIMH, 2010). The Slone Drug Dictionary (licensed from Boston 
University) was used to link medication components to corresponding drug products.
2.2. Statistical Analysis
After excluding mothers who did not complete the interview’s medication section (Figure 
1), there were 31 651 case mothers and 11 615 control mothers included in the analysis to 
assess the prevalence of atypical antipsychotic use during pregnancy and factors associated 
with use. We estimated the prevalence of any atypical antipsychotic use during pregnancy 
(including the month prior to conception due to imprecision of pregnancy and exposure 
timing) for case and control mothers separately. We estimated the prevalence of atypical 
antipsychotic use during pregnancy for two time-periods (1997–2004; 2005–2011) and 
across each month of pregnancy. To examine associations between maternal factors and 
atypical antipsychotic use during pregnancy, we calculated crude odds ratios (cOR) and 95% 
confidence intervals (CIs) using logistic regression. Associations were assessed separately 
for case and control mothers. We examined maternal age, race/ethnicity, education, previous 
births, pregnancy intention, pre-pregnancy obesity, folic acid use in the month before 
conception through the first month of pregnancy, illicit drug use in the three months before 
conception to pregnancy end, smoking or alcohol use during pregnancy, and anxiolytic, 
anticonvulsant, or antidepressant use, regardless of indication, during pregnancy.
We used logistic regression to calculate cOR and 95% CIs for the association between any 
early pregnancy (month prior to conception through the third pregnancy month) atypical 
antipsychotic use and specific selected birth defects. For the birth defect risk analysis, we 
excluded mothers who reported pre-pregnancy type 1 or 2 diabetes or anticonvulsant 
medication exposure in early pregnancy, due to their strong association with several birth 
defects (Correa et al., 2008; Werler et al., 2011). We also excluded mothers who reported 
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atypical antipsychotic use only outside of the exposure window and birth defects with <3 
exposed cases. There were 22 387 case and 11 470 control mothers eligible for the birth 
defect risk analysis (Figure 1). A priori, based on α = 0.05, β = 0.2 (i.e., power=0.80), and 
prevalence of atypical antipsychotic use during early pregnancy among controls of 0.1%, we 
estimated our smallest detectable odds ratios to range from 2.51 for any heart defect to 4.17 
for anorectal atresia/stenosis (Schlesselman, 1982). Given this, and to better align our 
analysis with recent American Statistical Association guidelines (Wasserstein et al., 2019) to 
evaluate findings in light of effect sizes with clinical or scientific relevance based on 
knowledge of the content area, regardless of a findings’ statistical significance, we 
considered associations to be elevated if there was a cOR ≥2.0. This threshold for an 
elevated association was set for all analyses. Analyses were conducted using SPSS 24.0.
3. Results
3.1. Prevalence of Atypical Antipsychotic Medication Use during Pregnancy
The use of atypical antipsychotics during pregnancy was rare; only 0.2% (67/31 651) of case 
mothers and 0.2% (17/11 615) of control mothers reported atypical antipsychotic medication 
use at any point during pregnancy. Among exposed case and control mothers, the most 
commonly reported atypical antipsychotics were similar and included quetiapine (case: 
52.2%; control: 52.9%), aripiprazole (case: 23.9%; control: 23.5%), olanzapine (case: 
11.9%; control: 17.6%), and risperidone (case: 13.4%; control: 11.8%). Among exposed 
mothers, less than 3% of case and no control mothers reported exposure to asenapine or 
ziprasidone. No case or control mothers reported exposure to other atypical antipsychotic 
medications. Among all exposed mothers, 6.0% (5/84 exposed mothers, including four case 
mothers and one control mother) took more than one atypical antipsychotic medication 
during pregnancy.
Despite rare overall use during pregnancy, the proportion of case mothers exposed to 
atypical antipsychotics increased from 0.1% (13/16 192) during 1997–2004 to 0.4% (54/15 
458) during 2005–2011. A more modest increase was observed for control mothers (0.1% 
[5/5,879] during 1997–2004 to 0.2% [12/5,736] during 2005–2011). The prevalence of 
atypical antipsychotic use decreased as the pregnancy progressed (Figure 2). This decrease 
was most pronounced from the month before conception through the third month of 
pregnancy, although the highest prevalence of atypical antipsychotic use was also observed 
during this period.
3.2. Factors Associated with Atypical Antipsychotic Medication Use during Pregnancy
Among control mothers, we observed elevated associations between atypical antipsychotic 
medication use during pregnancy and pre-pregnancy obesity (cOR: 4.0, 95% CI: 1.5–10.3), 
any illicit drug use in the three months before through the end of pregnancy (cOR: 9.6, 95% 
CI: 3.5–25.9), smoking during pregnancy (cOR: 3.2, 95% CI: 1.2–8.3), and alcohol use 
during pregnancy (cOR: 2.2, 95% CI: 0.8–5.7) (Table 1). Strong, elevated associations were 
also observed between atypical antipsychotic use during pregnancy and concurrent use of 
anxiolytics (cOR: 36.5, 95% CI: 11.7–113.9), anticonvulsants (cOR: 92.5, 95% CI: 31.5–
271.9), and antidepressants (cOR: 36.6, 95% CI: 13.5–99.3) (Table 1). Similar patterns were 
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observed for these variables among case mothers (Table 2), although associations with pre-
pregnancy obesity and alcohol use during pregnancy did not meet our threshold for elevated 
associations.
3.3. Early Pregnancy Atypical Antipsychotic Exposure and Risk for Selected Birth 
Defects
After applying exclusion criteria, there were 36 case and 12 control mothers exposed to any 
atypical antipsychotic in the month before conception through the third month of pregnancy. 
The birth defect categories with ≥3 exposed case mothers are delineated in Table 3. We 
observed elevated associations (cOR ≥2.0) between maternal atypical antipsychotic use 
during early pregnancy and conotruncal defects (6 exposed cases; cOR: 2.3, 95% CI: 0.9–
6.1), particularly with Tetralogy of Fallot (3 exposed cases; cOR: 2.5, 95% CI: 0.7–8.8). 
Associations between early pregnancy atypical antipsychotic use and cleft palate (4 exposed 
cases; cOR: 2.5, 95% CI: 0.8–7.6), anorectal atresia/stenosis (3 exposed cases; cOR: 2.8, 
95% CI: 0.8–9.9), and gastroschisis (3 exposed cases; cOR: 2.1, 95% CI: 0.6–7.3) were also 
elevated.
4. Discussion
This is the largest analysis to date on the association between any atypical antipsychotic 
medication use and risk for specific birth defects, which used careful clinical review of the 
birth defect outcomes. The prevalence of atypical antipsychotic medication use during 
pregnancy was rare (0.2%) in our study population, but increased from the early (1997–
2004) to the later (2005–2011) study years. Our findings are in line with other U.S.-based 
reports from administrative databases that suggest that atypical antipsychotic use is 
increasing among pregnant women, but our prevalence estimates were lower (Epstein et al., 
2013; Park et al., 2017; Toh et al., 2013). However, Hanley and Mintzes (2014) observed a 
0.2% prevalence of atypical antipsychotic prescriptions using claims data with a sample of 
privately-insured U.S. women from 2006–2011. Estimate variations may be due to 
methodological differences. Previous studies utilized administrative data that examined 
medications dispensed from pharmacies, while our study utilized retrospective case-control 
data with self-report of medications used. Differences in estimates may reflect differences 
between pregnant women who are Medicaid-insured (Epstein et al., 2013; Park et al., 2017) 
or those with private insurance (Hanley and Mintzes, 2014), and the NBDPS population, 
which included a population-based sample of pregnant women from sites across the United 
States. Triangulating evidence from all sources will be useful in determining accurate 
prevalence estimates of atypical antipsychotic use among U.S. pregnant women. In line with 
previous reports (e.g., Kallen et al., 2013; Park et al., 2017; Toh et al., 2013), we found a 
decreasing trend of atypical antipsychotic use across the months of pregnancy. We observed 
the most pronounced decrease during the 1st trimester, which corresponds with the timing of 
pregnancy recognition for most women (Branum and Ahrens, 2017). Although use of 
atypical antipsychotics declined in the 1st trimester of pregnancy, the highest prevalence of 
use occurred in early pregnancy, the period of fetal organogenesis.
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In our analysis, control mothers exposed to atypical antipsychotics were more likely to 
report pre-pregnancy obesity, illicit drug use before and during pregnancy, smoking during 
pregnancy, alcohol use during pregnancy, and use of other psychiatric medications. These 
results were largely mirrored among case mothers, although findings for pre-pregnancy 
obesity and alcohol use did not meet our threshold as elevated associations. Other studies 
have reported higher pre-pregnancy weight, obesity, and/or diabetes among those using 
atypical antipsychotics (Habermann et al., 2013; Park et al., 2017; Petersen et al., 2016; 
Sadowski et al., 2013), which may be related to these medications’ known association with 
metabolic syndrome (Rummel-Kluge et al., 2010). Pregnant women who use atypical 
antipsychotics have reported using illicit drugs and smoking more commonly during 
pregnancy compared to women not using atypical antipsychotics (e.g., Bellet et al., 2015; 
McKenna et al., 2005). Moreover, use of anxiolytics, anticonvulsants, and antidepressants 
are commonly reported by women concurrently using atypical antipsychotics (Park et al., 
2017; Petersen et al., 2016). The results for other factors examined in our analysis attempt to 
address conflicting evidence reported in other analyses. For example, it is unclear if pregnant 
women who take atypical antipsychotics are more likely to drink alcohol during pregnancy 
(Bellet et al., 2015; Park et al., 2017; Sadowski et al., 2013) or are less likely to plan their 
pregnancies (Habermann et al., 2013; McKenna et al., 2005). We observed an elevated 
association between atypical antipsychotic use and alcohol use among control mothers (but 
not case mothers), and we did not see an association with pregnancy planning. It is 
important to note that some of the factors examined in our analysis may be related to the 
underlying mental health disorder for which antipsychotics were prescribed (Boden et al., 
2012); we were unable to address confounding by indication in our analysis.
While some studies have reported an increased risk of having a baby with any major 
structural birth defect or any congenital heart defect after pregnancy exposure to atypical 
antipsychotics (Coughlin et al., 2015; Terrana et al., 2015), there have been few reports on 
associations with specific birth defects. In our unadjusted but restricted analysis, we 
observed elevated associations (defined in our analysis as cOR ≥2.0) between early 
pregnancy atypical antipsychotic use and conotruncal heart defects (and specifically the 
conotruncal defect Tetralogy of Fallot), cleft palate, anorectal atresia/stenosis, and 
gastroschisis. Results from a global pharmacovigilance safety analysis suggested there may 
be an increased risk for cleft palate, esophageal disorders, and anorectal disorders after 
exposure to any antipsychotic during pregnancy (Montastruc et al., 2016). Other studies 
have noted increased risks for cardiac septal defects (Habermann et al., 2013) and 
hypospadias (Reis and Kallen, 2008; Kallen et al., 2013) after any antipsychotic exposure 
during pregnancy; we did not observe these associations in our analysis. Given limited 
literature on atypical antipsychotic use in early pregnancy and risk for specific birth defects, 
the exploratory findings from this analysis merit replication with another large sample of 
exposed pregnancies and specific birth defects. Researchers may also consider examining 
links between specific medications and individual birth defects; some medications in this 
chemically heterogeneous group may be associated with greater risk of adverse pregnancy 
outcomes (e.g., risperidone) (Huybrechts et al., 2016; Ennis and Damkier, 2015).
The NBDPS is among the largest studies worldwide that examines risk factors for specific 
birth defects. Clinical geneticists and pediatric cardiologists reviewed all cases to ensure 
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eligibility and to classify birth defect cases using standard, detailed case definitions 
(Rasmussen et al., 2003; Reefhuis et al., 2015), which allowed us to accurately examine 
associations with specific defects. In the few instances when associations with specific 
defects have been examined previously, administrative data were used to capture birth defect 
outcomes, which is subject to misclassification bias overall (Grzeskowiak et al., 2012) and 
by specific birth defect (Cooper et al., 2008). We also focused on atypical antipsychotics 
specifically, whereas many previous studies have combined typical and atypical 
antipsychotics (e.g., Kulkarni et al., 2014; Montastruc et al., 2016; Petersen et al., 2016; Reis 
and Kallen, 2008). Notably, women who take typical antipsychotics during pregnancy are 
often prescribed these medications not for mental disorders but for antiemetic purposes 
(Goldstein et al., 2015; Reis and Kallen, 2008), with medications prescribed in lower doses 
and over shorter periods during pregnancy. These differences in the clinical use of the two 
types of antipsychotic medications could bias results towards the null if typical and atypical 
antipsychotics were collapsed. However, it is important to also note that the atypical 
antipsychotic class is a heterogeneous group of medications. Ideally, each medication and 
each birth defect pair should be examined; however, amassing a sufficient sample size to 
conduct this analysis proves to be a challenge in all available data sources.
There are also limitations of our study that should be considered. The NBDPS did not probe 
for specific mental disorders, which may have resulted in underreporting of atypical 
antipsychotic medication use and precluded our ability to examine the underlying 
indications for use. We also did not have information on the clinical course of the disorder 
for those who continued or discontinued treatment before and during pregnancy, on 
medication dosage, or on biomarkers for fetal drug exposure. NBDPS data collection ended 
with 2011 EDDs; new atypical antipsychotics (e.g., brexipiprazole, cariprazine) were not 
captured in this study. NBDPS does not include all birth defects; moreover, we excluded 
NBDPS-eligible birth defects with <3 exposed cases from our analysis in order to include 
only specific birth defects with sufficient data available to generate model estimates. In 
addition, study sites had varied ability to ascertain data on stillbirths and terminations over 
the study years (Reefhuis et al., 2015); it is unclear how these variations may have impacted 
our findings. While we restricted the birth defect analysis to account for variables that might 
be strong confounders for the association between atypical antipsychotic use and birth 
defects, the small number of exposed cases precluded our ability to adjust for additional 
confounders using multivariable models. Small exposed case counts also limited our ability 
to examine associations between individual atypical antipsychotics and specific birth 
defects. Although there were few women exposed overall to atypical antipsychotics, this 
analysis still makes an important contribution given the limited literature on associations 
with specific birth defects, and the growing use of these medications.
Our findings support existing recommendations for the close monitoring of reproductive-
aged women with mental health conditions that are treated by antipsychotic medications 
(ACOG, 2008; Zacher et al., 2013). In general, women who use atypical antipsychotics 
during pregnancy represent a subgroup of women at heightened baseline risk for having a 
baby with a major birth defect due to risks associated with the underlying indication 
(Cannon et al., 2002; Rusner et al., 2016), associated behaviors (e.g., smoking and substance 
use), and comorbidities (e.g., obesity, diabetes) that increase the risk of adverse pregnancy 
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and infant outcomes, including major birth defects (Boden et al., 2012; Jablensky et al., 
2005; Janssen et al., 2015; Parnell et al., 2017; US DHHS, 2014). Women with conditions 
treated by atypical antipsychotics generally access healthcare services before pregnancy 
(Toh et al., 2013), and health education could be provided to reduce pre-pregnancy obesity, 
smoking, and other correlates of atypical antipsychotic use to improve maternal and infant 
health in this population. Furthermore, we observed that some pregnant women discontinued 
the use of their medications around the time of pregnancy recognition (in the 1st trimester), 
although this also means that for many women, exposure during the period of fetal 
organogenesis would already have occurred. Ideally, healthcare providers would work with 
women taking atypical antipsychotics prior to pregnancy in order to determine a course of 
clinical action for before and during pregnancy that carefully weighs the potential for illness 
relapse and the consequent risks to the mother and baby related to that, against the potential 
risk of maintaining atypical antipsychotic treatment during pregnancy.
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Figure 1. 
Participant selection for the estimation of prevalence and maternal factors associated with 
atypical antipsychotic use during pregnancy, and associations between early pregnancy 
atypical antipsychotic use and specific birth defects, National Birth Defects Prevention 
Study, 1997–2011
aSample used in the calculation of prevalence estimates for atypical antipsychotic 
medication use during pregnancy and maternal factors associated with use. Pregnancy was 
defined as the month prior to conception through the end of pregnancy. bAnticonvulsant 
medications included in this exclusion can be found in the National Institute of Mental 
Health anticonvulsant medication list (NIMH, 2010). cEarly pregnancy was defined as the 
month prior to conception through the third month of pregnancy. dTotal sample of case and 
control mothers included in the analysis of early pregnancy atypical antipsychotic use and its 
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association with birth defects; includes cases and controls exposed and unexposed to 
atypical antipsychotic medications.
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Figure 2. 
Distribution of any atypical antipsychotic medication use across pregnancy months,a 
National Birth Defects Prevention Study, 1997–2011
aB1 corresponds to the month before conception, P1–P9 correspond to the 1st–9th month of 
pregnancy.
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TABLE 1
Maternal sociodemographic and health factors and any atypical antipsychotic medication usea during 
pregnancy among control mothers, National Birth Defects Prevention Study, 1997–2011
Maternal Factors
Exposed to atypical antipsychotic 
medications during pregnancyb,c 
(N = 17)
Unexposed to atypical antipsychotic 
medications during pregnancyb,c (N 
= 11 598) cORd 95% CI
Age (years)
 <35 13 (76.5%) 9,962 (85.9%) 0.5 [0.2, 1.6]
 ≥35 [ref]   4 (23.5%) 1,636 (14.1%)
Non-Hispanic white race/ethnicity
 Yes 12 (70.6%) 6,742 (58.2%) 1.7 [0.6, 4.9]
 No [ref]   5 (29.4%) 4,850 (41.8%)
Education (years)
 >12   9 (52.9%) 6,845 (59.7%) 0.8 [0.3, 2.0]
 ≤12 [ref]   8 (47.1%) 4,621 (40.3%)
Number of previous birthse
 One or more 11 (64.7%) 7,042 (60.7%) 1.2 [0.4, 3.2]
 None [ref]   6 (35.3%) 4,552 (39.3%)
Pregnancy intentionf
 Wanted to be pregnant then   8 (57.1%) 5,601 (59.3%) 0.9 [0.3, 2.6]
 Other intention [ref]   6 (42.9%) 3,847 (40.7%)
Pre-pregnancy obesity (BMI kg/m2)
 ≥30   8 (47.1%) 2,035 (18.3%) 4.0 [1.5, 10.3]
 <30 [ref]   9 (52.9%) 9,080 (81.7%)
Any early pregnancy folic acid useg
 Yes   5 (29.4%) 6,135 (52.9%) 0.4 [0.1, 1.1]
 No [ref] 12 (70.6%) 5,462 (47.1%)
Any illicit drug useh
 Yes   6 (35.3%) 626 (5.4%) 9.6 [3.5, 25.9]
 No/Not Known [ref] 11 (64.7%) 10 972 (94.6%)
Any smokingb
 Yes   7 (41.2%) 2,087 (18.1%) 3.2 [1.2, 8.3]
 No [ref] 10 (58.8%) 9,420 (81.9%)
Any alcohol useb
 Yes 10 (58.8%) 4,544 (39.6%) 2.2 [0.8, 5.7]
 No [ref]   7 (41.2%) 6,932 (60.4%)
Other Psychiatric Medication Use
Anxiolytic medicationsb,i
 Yes   4 (23.5%) 97 (0.8%) 36.5 [11.7, 113.9]
 No [ref] 13 (76.5%) 11 500 (99.2%)
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Maternal Factors
Exposed to atypical antipsychotic 
medications during pregnancyb,c 
(N = 17)
Unexposed to atypical antipsychotic 
medications during pregnancyb,c (N 
= 11 598) cORd 95% CI
Anticonvulsant medicationsb,i
 Yes   5 (29.4%) 52 (0.4%) 92.5 [31.5, 271.9]
 No [ref] 12 (70.6%) 11 545 (99.6%)
Antidepressant medicationsb,i
 Yes 11 (64.7%) 553 (4.8%) 36.6 [13.5, 99.3]
 No [ref]   6 (35.3%) 11 037(95.2%)
a
Mothers of control infants reported use ot the following atypical antipsychotic medications: aripiprazole, olanzapine, quetiapine, and risperidone;
b
From the month before conception to pregnancy end;
cColumn counts and percentages may not equal the expected N due to missing data on maternal factors;
d
Bolded results in the table reflect elevated associations with cOR ≥2.0;
e
Includes previous live births and stillbirths;
fOther intention includes women who wanted to wait until later to become pregnant, those who did not want to be pregnant at all, and those who 
did not care about becoming pregnant;
g
From the month before conception through the first month of pregnancy;
h
From three months before conception to pregnancy end;
i
Medications included in the anxiolytic, anticonvulsant, and antidepressant medication categories can be found in the National Institute of Mental 
Health mental health medication list;
Abbreviations: 95% CI, 95% confidence interval; cOR, crude (unadjusted) odds ratio; Ref, reference category.
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TABLE 2
Maternal sociodemographic and health factors and any atypical antipsychotic medication usea during 
pregnancy among case mothers, National Birth Defects Prevention Study, 1997–2011
Maternal Factors
Exposed to atypical antipsychotic 
medications during 
pregnancyb,c(N = 67)
Unexposed to atypical antipsychotic 
medications during pregnancyb,c (N 
= 31 584) cORd 95% CI
Age (years)
 <35 51 (76.1%) 26 809 (84.9%) 0.6 [0.3, 1.0]
 ≥35 [ref] 16 (23.9%)   4775 (15.1%)
Non-Hispanic white race/ethnicity
 Yes 41 (61.2%) 18 569 (58.8%) 1.1 [0.7, 1.8]
 No [ref] 26 (38.8%) 13 008 (41.2%)
Education (years)
 >12 28 (42.4%) 17 733 (56.8%) 0.6 [0.3, 0.9]
 ≤12 [ref] 38 (57.6%) 13 510 (43.2%)
Number of previous birthse
 One or more 36 (53.7%) 18 259 (57.8%) 0.9 [0.5, 1.4]
 None [ref] 31 (46.3%) 13 311 (42.4%)
Pregnancy intentionf
 Wanted to be pregnant then 25 (44.6%) 15 178 (58.2%) 0.6 [0.3, 1.0]
 Other intention [ref] 31 (55.4%) 10 922 (41.8%)
Pre-pregnancy obesity (BMI kg/m2)
 ≥30 21 (31.3%)   6244 (20.6%) 1.8 [1.1, 2.9]
 <30 [ref] 46 (68.7%) 24 002 (79.4%)
Any early pregnancy folic acid useg
 Yes 33 (49.3%) 16 536 (52.4%) 0.9 [0.6, 1.4]
 No [ref] 34 (50.7%) 15 047 (47.6%)
Any illicit drug useh
 Yes 16 (23.9%) 1964 (6.2%) 4.7 [2.7, 8.3]
 No/Not Known [ref] 51 (76.1%) 29 620 (93.8%)
Any smokingb
 Yes   40 (60.6%)   6339 (20.2%) 6.1 [3.7, 10.0]
 No [ref]   26 (39.4%) 24 995 (79.8%)
Any alcohol useb
 Yes 28 (42.4%) 11 931 (38.3%) 1.2 [0.7, 1.9]
 No [ref] 38 (57.6%) 19 257 (61.7%)
Other Psychiatric Medication Use
Anxiolytic medicationsb,i
 Yes   7 (10.4%) 289 (0.9%) 12.6 [5.7, 27.9]
 No [ref] 60 (89.6%) 31 286 (99.1%)
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Maternal Factors
Exposed to atypical antipsychotic 
medications during 
pregnancyb,c(N = 67)
Unexposed to atypical antipsychotic 
medications during pregnancyb,c (N 
= 31 584) cORd 95% CI
Anticonvulsant medicationsb,i
 Yes 25 (37.3%) 215 (0.7%) 86.8 [52.0, 145.0]
 No [ref] 42 (62.7%) 31 366 (99.3%)
Antidepressant medicationsb,i
 Yes 44 (66.7%) 1846 (5.9%) 32.2 [19.3, 53.8]
 No [ref] 22 (33.3%) 29 707 (94.1%)
a
Mothers of case infants reported use ot the following atypical antipsychotic medications: aripiprazole, asenapine, olanzapine, quetiapine, 
risperidone, and ziprasidone;
b
From the month before conception to pregnancy end;
cColumn counts and percentages may not equal the expected N due to missing data on maternal factors;
d
Bolded results in the table reflect elevated associations with cOR ≥2.0;
e
Includes previous live births and stillbirths;
fOther intention includes women who wanted to wait until later to become pregnant, those who did not want to be pregnant at all, and those who 
did not care about becoming pregnant.
g
From the month before conception through the first month of pregnancy;
h
From three months before conception to pregnancy end;
i
Medications included in the anxiolytic, anticonvulsant, and antidepressant medication categories can be found in the National Institute of Mental 
Health mental health medication list;
Abbreviations: 95% CI, 95% confidence interval; cOR, crude (unadjusted) odds ratio; Ref, reference category.
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TABLE 3
Associations between any atypical antipsychotic medication use from one month before conception through 
the third month of pregnancy and specific selected birth defects,a National Birth Defects Prevention Study 
(NBDPS), 1997–2011
Defect
Atypical Antipsychotic 
Medication Exposedb,c N
Atypical Antipsychotic 
Medication Unexposedb,d N cOR (95% CI)e
Controls 12 11,458
Any heart defect 18 11,803 1.5 (0.7, 3.0)
 Conotruncal defects   6 2,495 2.3 (0.9, 6.1)
  Tetralogy of Fallot   3 1,154 2.5 (0.7, 8.8)
 LVOTO   4 2,169 1.8 (0.6, 5.5)
 RVOTO   3 2,037 1.4 (0.4, 5.0)
 Septal defects   4 4,529 0.8 (0.3, 2.6)
  Atrial septal defect (secundum or NOS)   4 2,914 1.3 (0.4, 4.1)
Any orofacial cleftf   7 4,574 1.4 (0.6, 3.7)
 Cleft palatef   4 1,539 2.5 (0.8, 7.6)
 Cleft lip +/− cleft palatef   3 3,035 0.9 (0.3, 3.3)
Anorectal atresia/stenosis   3 1,028 2.8 (0.8, 9.9)
Hypospadias, 2/3rd degreef   3 2,510 0.8 (0.2, 2.9)
Craniosynostosis   3 1,567 1.8 (0.5, 6.5)
Gastroschisis   3 1,398 2.1 (0.6, 7.3)
a
This table includes NBDPS birth defects with ≥3 exposed cases. Cases were included in the higher order defect category (e.g., “any heart defect”) 
even if the more detailed birth defect category was excluded (e.g., hypoplastic left heart syndrome, coarctation of the aorta). The total sample of 
cases presented in the Method section does not sum to Table 3 individual defects reported as cases may have ≥1 eligible defect;
bAtypical antipsychotic medication components with case or control mother exposure included aripiprazole, asenapine, olanzapine, quetiapine, 
risperidone, and ziprasidone;
c
Mothers exposed to atypical antipsychotics from the month before conception through the third month of pregnancy;
d
Mothers unexposed to atypical antipsychotics from three months before conception through the end of pregnancy;
e
Bolded results in the table reflect elevated associations with cOR ≥2.0;
fAs any orofacial clefts, cleft palate, and cleft lip +/− cleft palate were only ascertained by a subset of the study sites in certain years, and 
hypospadias only affects male infants, controls for these analyses were similarly restricted. For orofacial clefts, cleft palate, and cleft lip +/− cleft 
palate, there were 11 324 unexposed controls and 12 controls who were exposed to atypical antipsychotic medication in early pregnancy. For 
hypospadias, there were 5,837 unexposed controls and 9 controls who were exposed to atypical antipsychotic medication in early pregnancy;
Abbreviations: 95% CI, 95% confidence interval; cOR, crude (unadjusted) odds ratio; LVOTO, left ventricular outflow tract obstruction; RVOTO, 
right ventricular outflow tract obstruction; NOS, not otherwise specified.
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